


To secure capital growth from a portfolio of securities of companies engaged in Health and Pharmaceuticals and Biotechnology.
| Name | % Net Assets | 
|---|---|
| PFIZER INC | 0.0% | 
| ASTRAZENECA | 0.0% | 
| SANOFI-AVENTIS | 0.0% | 
| ABBOTT LABORATORIES | 0.0% | 
| MERCK & CO INC | 0.0% | 
| ROCHE HLDG AG | 0.0% | 
| NOVARTIS AG | 0.0% | 
| GLAXOSMITHKLINE | 0.0% | 
| JOHNSON & JOHNSON | 0.0% | 
| WYETH | 0.0% | 
| Key | % Net Assets | 
|---|---|
| 0.0% | |
| 0.0% | |
| 0.0% | |
| 0.0% | |
| 100% | 
| Date | 20-Aug-2025 | 
|---|---|
| NAV | 107.00p | 
| Currency | GBP | 
| Change | 1.10p | 
| % | 1.04% | 
| YTD change | -7.30p | 
| YTD % | -6.39% | 
| Fund Inception | 21/11/2000 | 
|---|---|
| Fund Manager | Ali Toutounchi | 
| TER | 1.15 (31-Dec-2013) | 
| Minimum Investment | |
|---|---|
| Initial | £1000 | 
| Additional | n/a | 
| Savings | n/a | 
| Charges | |
|---|---|
| Initial | n/a | 
| Annual Mang't | 1.00% | 
| Exit | n/a | 
| Name | % | 
|---|---|
| Standard deviation | 0.01 | 
| Sharpe ratio | -0.08 | 
You are here: research